IP Library Granted Patent US 11,298,311
Granted Patent B2
US 11,298,311 · App. 16/795,921 · Granted Apr 12, 2022

Stable silk protein fragment compositions

Inventors: Gregory H. Altman (Providence, RI); Rebecca L. Lacouture (Needham, MA); Rachel Lee Dow (Medford, MA); Rachel M. Lind (Somers, NY); Dylan S. Haas (Yorktown Heights, NY)
Assignee: EVOLVED BY NATURE, INC.
A61K8/64A45D33/00A61K8/02A61K8/0216A61K8/042A61K8/19A61K8/27A61K8/29A61K8/365A61K8/4953A61K8/676A61K8/735A61K8/922A61K8/97A61K8/9789A61K8/9794A61K8/987A61K9/08A61K38/00A61K38/012A61Q17/04A61Q19/00A61Q19/007A61Q19/02A61Q19/08C07K1/12C07K14/43586A61K2800/591A61K2800/72A61K2800/74A61K2800/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,298,311
App. No.
16/795,921
Granted
Apr 12, 2022
Kind
B2
Abstract

A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.

Claims (16)

1. A composition comprising silk fibroin protein fragments having an average weight average molecular weight selected from 40 kDa to 45 kDa, from 45 kDa to 50 kDa, or from 50 kDa to 55 kDa, and a polydispersity from about 1.5 to about 3.0, wherein:

the silk fibroin protein fragments are substantially devoid of sericin;

the composition is substantially homogeneous;

the composition includes between 0 ppm to about 500 ppm of inorganic residuals and between 0 ppm to about 500 ppm of organic residuals;

and the composition does not spontaneously or gradually gelate and does not visibly change in color or turbidity when in a solution for at least 10 days.

2. The composition of claim 1 , wherein the inorganic residuals include lithium bromide and wherein the organic residuals include sodium carbonate.

3. The composition of claim 1 , wherein the concentration of silk fibroin protein fragments in the composition is from about 0.1 wt % to about 30.0 wt %.

4. The composition of claim 1 in the form of a solution.

5. The composition of claim 1 , further comprising one or more therapeutic agents.

6. The composition of claim 5 , wherein the one or more therapeutic agents comprise vitamin C or a derivative thereof.

7. The composition of claim 5 , wherein the one or more therapeutic agents comprise hyaluronic acid or a salt thereof.

8. The composition of claim 5 , wherein the one or more therapeutic agents comprise an alpha hydroxy acid.

9. The composition of claim 8 , wherein the alpha hydroxy acid selected from the group consisting of glycolic acid, lactic acid, tartaric acid and citric acid.

10. The composition of claim 1 , wherein the silk fibroin protein fragments are hypoallergenic.

11. The composition of claim 1 , wherein the composition does not spontaneously or gradually gelate and does not visibly change in color or turbidity when in a solution for at least 30 days.

12. The composition of claim 7 , wherein the hyaluronic acid or salt thereof has a concentration of about 0.5 wt % to about 10.0 wt %.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: ALTMAN, GREGORY H.; HORAN, REBECCA L.; DOW, RACHEL LEE; LIND, RACHEL M.; HAAS, DYLAN S.
To: SILK THERAPEUTICS, INC.
Reel/Frame 061602/0219 →
CHANGE OF NAME Recorded Oct 31, 2022
From: SILK THERAPEUTICS, INC.
To: SILK, INC.
Reel/Frame 061824/0877 →
CHANGE OF NAME Recorded Oct 31, 2022
From: SILK, INC.
To: EVOLVED BY NATURE, INC.
Reel/Frame 061824/0908 →
Continuity (8)
Continuation 16453620 · Jun 26, 2019
Continuation 16184098 · Nov 8, 2018
Continuation 14876792 · Oct 6, 2015
Continuation 14503021 · Sep 30, 2014
Provisional Application 62036450 · Aug 12, 2014
Provisional Application 62000928 · May 20, 2014
Provisional Application 61884820 · Sep 30, 2013
Related Publication 20200188269A1 · Jun 18, 2020
Cited By (2)
US 12,403,177 US 12,703,725